Previous 10 | Next 10 |
Biotechnology company Evelo Biosciences (NASDAQ:EVLO) entered into a securities purchase agreement with investors over direct offering of 54,246,358 shares at $1.46 per share. The offering will result in gross proceeds of $79.2M. The offering is being led by Evelo Founder Flagship Pionee...
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities purchase agreement with investors in a registered ...
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence of the First Quarter 2022 Financial Results (Unaudited) section, the dates should be &...
Evelo Biosciences press release (NASDAQ:EVLO): Q1 GAAP EPS of -$0.56 beats by $0.04. As of December 31, 2021, cash and cash equivalents were $39.6 million, as compared to cash and cash equivalents of $68.4 million as of March 31, 2021. For further details see: Evelo Biosciences GAAP EPS...
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2022. “This ...
John Maraganore and Tassos Gianakakos, the former CEOs of, respectively, Alnylam Pharmaceuticals (ALNY) and MyoKardia, are joining Evelo Biosciences (NASDAQ:EVLO) as strategic advisors. Maraganore was Alnylam's founding CEO and just left the company last year, while Gianakakos served as MyoKa...
Gainers: Vallon Pharmaceuticals (VLON) +80%. Blueknight Energy Partners (BKEP) +38%. Moving iMage Technologies (MITQ) +37%. RISE Education Cayman (REDU) +15%. Sky Harbour Group (SKYH) +14%. GWG Holdings (GWGH) +14%. Evelo Biosciences (EVLO) +13%. Chindata Group Holdings (CD) +13%. Shattuck La...
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that John Maraganore, Ph.D., founder and longtime former CEO of Alnylam Pharmaceuticals...
Evelo Biosciences (NASDAQ:EVLO) said it will put the EDP1867 program for eczema on hold after clinical benefit was not seen in a phase 1 trial. The company evaluated EDP1867 in a phase 1b trial which included healthy volunteers and patients with moderate atopic dermatitis (ecze...
–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022– –Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023– –Faster release capsule cohort to be added to on-going Phase 2 trial...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
NASDAQ Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...